Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB14 plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for driver gene-negative advanced or metastatic non-small cell lung cancer
CTR20251153Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB14, tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sinocelltech Group Limited. Started Apr 2025; status: active.
02
Drugs
SCTB14tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251153.